Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

COVID-19: Mithramycin analogs as inhibitors of the complex ACE2- SARS-Cov-2 RBD (receptor-binding domain)

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20200527001
Publicado:
27/05/2020
Caducidad:
28/05/2021
Resumen:
A Spanish company working in pharmaceutical development is the only institution in the world with a library of dozens of mithramycin analogs and the know-how to make further analogs as guided by molecular dynamics to improve the inhibition of the complex ACE2-SARS-Cov-2 RBD (receptor-binding domain). The company is looking for partners for research or technical cooperation agreements.

Details

Tittle:
COVID-19: Mithramycin analogs as inhibitors of the complex ACE2- SARS-Cov-2 RBD (receptor-binding domain)
Summary:
A Spanish company working in pharmaceutical development is the only institution in the world with a library of dozens of mithramycin analogs and the know-how to make further analogs as guided by molecular dynamics to improve the inhibition of the complex ACE2-SARS-Cov-2 RBD (receptor-binding domain). The company is looking for partners for research or technical cooperation agreements.
Description:
Mithramycin has been shown by in silico studies to block the interaction between the viral spike protein domain RBD and the human receptor ACE2, in an allosteric site not affecting the biological function of ACE2, but interrupting the protein-protein interaction that is recognized as the main point of entry of the virus in the human cells.
A Spanish company, working in research and development of pharmaceutical products, is exploring the inhibition of the complex ACE2- SARS-Cov-2 RBD by in silico and in vitro methods. The company is seeking futher cooperation with research institutions and companies in Molecular Dynamics or antiviral screening through research cooperation agreements or technical cooperation agreements.
Advantages and Innovations:
If a suitable mithralog is found with proper antiviral properties (and acceptable toxicity), development of such can proceed quickly, based on previous experience with other mithralogs, that are now about to enter the clinic (for oncology).
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how,Exclusive Rights
CommeR Statunts Regarding IPR Status:
Substance Patent to be filed once the best candidate is identified.

Partner sought

Type and Role of Partner Sought:
Research -Y- development partners (industrial or academic) are sought in order to further explore the potential of the Mithramycin analogs as inhibitors of the Cov-2 virus via research or technical cooperation agreements.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06002007 Ensayos in vitro, experimentos
06002004 Ingeniería de proteínas
06001002 Investigaciones clínicas, ensayos
06002008 Microbiología
06001015 Productos farmacéuticos / medicamentos